Manufacturing site not PQ-ready during dossier submission – how to defend manufacturing readiness








Published on 29/01/2026

Defending Manufacturing Readiness When Your Site Isn’t PQ-Ready During Dossier Submission

Pharmaceutical manufacturers often face stringent regulatory requirements, particularly during WHO Prequalification (PQ) submissions. An alarming finding can be a manufacturing site that is not PQ-ready. This scenario can jeopardize timelines and affect commercial success. The goal of this article is to equip you with a structured playbook addressing immediate actions and long-term strategies to assure compliance and readiness for audits and inspections.

By following this playbook, you will be able to identify symptoms of non-readiness on the manufacturing floor or laboratory, conduct thorough investigations, implement effective Corrective and Preventive Actions (CAPA), and ensure constant monitoring. You will also understand how to manage changes effectively and be inspection-ready based on evidence.

Symptoms/Signals on the Floor or in the Lab

When assessing whether a manufacturing site is PQ-ready, it is

essential to observe specific symptoms that may indicate compliance issues. Early detection can significantly reduce the risks associated with regulatory scrutiny. Below are common signals that denote potential readiness concerns:

  • Increased Deviations: A surge in discrepancies or deviations from standard operating procedures (SOPs).
  • Quality Control Failures: Higher-than-usual batch failures in quality control (QC) testing, such as out-of-specification (OOS) results.
  • Equipment Malfunctions: Frequent equipment breakdowns or performance inconsistencies in key manufacturing equipment.
  • Training Records Issues: Gaps in employee training records or lack of documentation supporting their GMP compliance.
  • Documentation Errors: Missing or incomplete batch records, and deviations being recorded inconsistently.

Likely Causes

Understanding probable causes is vital for diagnosing the root of the non-readiness issue. These causes can be categorized into six groups, often termed the “6 Ms”: Materials, Method, Machine, Man, Measurement, and Environment.

Pharma Tip:  Stability data gaps during inspection preparation – documentation gaps reviewers flag

1. Materials:

  • Composition changes or raw material non-compliance.
  • Inadequate supplier qualification processes.

2. Method:

  • Lack of robust Standard Operating Procedures (SOPs).
  • Inconsistent operating methods across shifts or teams.

3. Machine:

  • Outdated or poorly maintained equipment.
  • Inconsistent calibration or lack of preventive maintenance records.

4. Man:

  • Insufficient training for personnel on GMP compliance.
  • Lack of personnel engagement or ownership of processes.

5. Measurement:

  • Poor data management leading to unreliable metrics.
  • Inadequate monitoring systems that fail to capture critical performance indicators.

6. Environment:

  • Inappropriate environmental controls such as temperature or humidity excursions.
  • Inadequate cleanliness standards in production or laboratory areas.

Immediate Containment Actions (First 60 Minutes)

The initial reaction to discovering that the manufacturing site is not PQ-ready should focus on containment. Immediate actions can help prevent further complications. Here are crucial steps to take within the first hour:

  • Alert Your Team: Notify all relevant teams, focusing on production, QC, and quality assurance (QA), to halt any processes contributing to non-compliance.
  • Document the Incident: Begin documentation of the incident immediately, including time, personnel involved, and initial findings.
  • Isolate Affected Areas: Section off areas of the facility directly impacted, ensuring no further processing occurs.
  • Review Incoming Materials: Verify that no affected materials are released into the production area until they have been cleared.

Investigation Workflow

After immediate containment, a structured investigation must follow. Gathering data and understanding the underlying issues are critical to formulating an effective response. Here’s how to perform a detailed investigation:

  1. Collect Data: Gather all relevant documentation, including batch records, equipment logs, deviations, and any other records related to the issue.
  2. Conduct Interviews: Speak with affected staff members to gain insight into the symptom’s situational context.
  3. Review QC Results: Examine quality control data for recent batches to identify trends leading to the observed symptoms.
  4. Data Analysis: Analyze collected data using appropriate statistical methods to identify potential patterns or anomalies.

Having a thorough understanding of the problem allows for focused remediation strategies while aligning with regulatory expectations. Inspection agencies like the FDA or EMA will expect you to present a comprehensive analysis of your findings.

Pharma Tip:  Deviation history questioned during variation management – preventing PQ suspension

Root Cause Tools

To effectively address compliance concerns, identifying the root cause is essential. Various root cause analysis (RCA) tools can facilitate this process:

1. 5-Why Analysis:

This tool helps drill down into the root cause by repeatedly asking “why” a problem occurred until the fundamental issue is identified..

2. Fishbone Diagram:

Also known as the Ishikawa diagram, it allows teams to visualize the causes and categorize them systematically. It’s particularly useful in team settings where collaboration is required for identification.

3. Fault Tree Analysis:

Employs a top-down approach to identify potential causes of a system failure. It is beneficial in complex environments where multiple systems could contribute to the symptoms observed.

The choice of which tool to use depends on the complexity of the issue at hand and the multidisciplinary team’s availability.

CAPA Strategy

Implementing an effective CAPA strategy is crucial after identifying root causes. The CAPA process should be divided into three main components:

Related Reads

Correction:

  • Immediate action taken to resolve the identified non-conformance.
  • Document all actions taken to rectify the issue to ensure clarity during audits.

Corrective Action:

  • Actions designed to address the root cause, preventing recurrence.
  • Implement changes to SOPs, re-train personnel, or upgrade equipment as necessary.

Preventive Action:

  • Long-term solutions intended to mitigate future risks before they lead to compliance issues.
  • Regular review of processes and proactive management of change controls.

Control Strategy & Monitoring

A robust control strategy is essential for maintaining compliance. Implement a consistent monitoring program that includes:

  • Statistical Process Control (SPC): Utilize SPC tools to identify trends or variations that could signal issues.
  • Regular Sampling: Institute routine inspection schedules based on critical control points.
  • Alarms and Alerts: Set up alarm systems to notify personnel of potential deviations from critical parameters in real-time.
  • Verification Protocols: Regularly verify and validate that all processes remain in control and align with established regulatory standards.

Validation / Re-qualification / Change Control Impact

Changes made during this process may have validation or re-qualification implications. Assess the following:

  • Validation: Determine whether any changes necessitate revalidation of affected processes or equipment.
  • Re-qualification: If major equipment has been malfunctioning, re-qualification must occur to ensure compliance and readiness.
  • Change Control: Revisit your change control procedures to ensure all implemented changes are documented, evaluated, and approved.
Pharma Tip:  CAPA effectiveness doubted during WHO PQ assessment – documentation gaps reviewers flag

Failing to assess these impacts can have serious compliance implications and lead to unforeseen challenges during future inspections.

Inspection Readiness: What Evidence to Show

Demonstrating inspection readiness requires well-organized documentation. Prepare the following evidence:

  • Records: Comprehensive records detailing deviations, CAPA, and changes made.
  • Logs: Equipment logs showing maintenance and calibration activities post-deviation.
  • Batch Documentation: Ensured that all batch records are accurate, complete, and compliant.
  • Deviations Management: Well-documented deviations alongside resolution strategies implemented throughout the investigation.

Be prepared to explain your processes clearly and present evidence justifying your position during inspections by regulatory bodies like the WHO or the MHRA.

FAQs

What are the most common reasons for a site not being PQ-ready?

Common issues include inadequate training, equipment malfunctions, documentation errors, and material non-compliance.

How quickly should I act if I discover my site is not PQ-ready?

Immediate containment actions should be taken within the first 60 minutes of discovery to limit impact.

What documentation is critical for supporting inspection readiness?

Batch records, deviation logs, CAPA documentation, and equipment maintenance records are essential.

How do I ensure my CAPA is effective?

Regularly review your CAPA outcomes, track implementation status, and ensure training is effective post-implementation.

Why is continuous monitoring important?

Continuous monitoring helps identify issues before they result in non-compliance, ensuring ongoing readiness.

Do changes to processes require re-validation?

Yes, any substantial changes in processes or equipment should trigger re-validation and re-qualification efforts.

What is the significance of root cause analysis?

Root cause analysis identifies underlying issues to prevent recurrence, promoting sustainable compliance improvements.

What stakeholders should be included in the investigation process?

Involve cross-functional teams, including production, QC, QA, engineering, and management, to ensure comprehensive analysis.